YEAR
- 2018.06.22 What consequence is anticipated by the emergence of novel SPPARMa agent developed so as to achieve an improved safety/efficacy balance? Motonobu Anai, Toshiya Tanaka, Tatsuhiko Kodama.Jpn Pharmacol Ther. 46: 471-480 (2018).
- 2018.07.05 Tyrosine Sulfation Restricts the Conformational Ensemble of a Flexible Peptide, Strengthening the Binding Affinity for an Antibody. Miyanabe K, Yamashita T, Abe Y, Akiba H, Takamatsu Y, Nakakido M, Hamakubo T, Ueda T, Caaveiro JMM, Tsumoto K.Biochemistry. 2018 07 17;57(28):4177-4185. doi: 10.1021/acs.biochem.8b00592
- 2018.12.20 Transcriptome-wide identification of A-to-I RNA editing sites using ICE-seq. Okada S, Ueda H, Noda Y, Suzuki T.Methods. 2019 03 01;156:66-78. doi: 10.1016/j.ymeth.2018.12.007
- 2018.04.03 Toward rational antibody design: recent advancements in molecular dynamics simulations. Yamashita T.Int. Immunol. 2018 04 03;30(4):133-140. doi: 10.1093/intimm/dxx077
- 2018.11.01 The Interferon (IFN) Class of Cytokines and the IFN Regulatory Factor (IRF) Transcription Factor Family. Negishi H, Taniguchi T, Yanai H.Cold Spring Harb Perspect Biol. 2018 11 01;10(11). doi: 10.1101/cshperspect.a028423
- 2018.04.20 The Influence of Pemafibrate (Parmodia Tablet) on Liver and Renal Function Toshiya Tanaka, Motonobu Anai, and Tatsuhiko KodamaJ Pharmacol Ther. 2017 Nov 20; 45(11):1775-1785.
- 2018.05.03 Structural Properties of the Human Protease-Activated Receptor 1 Changing by a Strong Antagonist. Spoerri PM, Kato HE, Pfreundschuh M, Mari SA, Serdiuk T, Thoma J, Sapra KT, Zhang C, Kobilka BK, Müller DJ.Structure. 2018 06 05;26(6):829-838.e4. doi: 10.1016/j.str.2018.03.020
- 2018.08.29 Structural mechanisms of selectivity and gating in anion channelrhodopsins. Kato HE, Kim YS, Paggi JM, Evans KE, Allen WE, Richardson C, Inoue K, Ito S, Ramakrishnan C, Fenno LE, Yamashita K, Hilger D, Lee SY, Berndt A, Shen K, Kandori H, Dror RO, Kobilka BK, Deisseroth K.Nature. 2018 09;561(7723):349-354. doi: 10.1038/s41586-018-0504-5
CLOSE